CTIS2022-501759-95-00进行中（未招募）1 期
An exploratory, prospective, multicenter, randomized, double blind, placebo + sham device controlled, study to assess the safety, usability, and initial efficacy of the ViXe combination for intravesical administration of XEOMIN® in the treatment of female patients with idiopathic overactive bladder (OAB). - ViXe-CLP-0002
Vensica Medical Ltd.0 个研究点目标入组 50 人开始时间: 2022年12月15日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
入选标准
- •Female aged between 18 and 80 years at the time of signing the informed consent., Females with childbearing potential must have a negative pregnancy test and must practice an acceptable method of birth control, from at least 4 weeks before treatment until 12 weeks after treatment., Signed written informed consent., Diagnosis of OAB for at least 6 months prior to screening, determined by documented subject history., At least 8 voiding episodes/day based on 3-consecutive days voiding diary at screening., OAB with at least 6 leaking episodes associated with urgency (UUI), demonstrated on 3-consecutive days voiding diary, and at least one episode per day., Subject is mentally competent with the ability to understand and comply with the requirements of the study., Subject is willing and able to initiate self-catheterization post treatment, if required., Subject with inadequate response to conservative medication treatment/s as defined by the investigator., Subject agrees to attend all follow-up evaluations and is willing and capable to fill out voiding diaries and questionnaires completely and accurately and is willing to complete required exams and tests.
排除标准
- •Previous participation in another study with any investigational drug or device within the past 90 days., Subject with PVR = 200 ml based on bladder ultrasound at screening visit., Current or recurrent urinary tract infection (3 or more infections in the last 6 months), or presence of urinary fistula per physical examination, or known significant urinary tract obstruction or urethral stricture., Subject who received botulinum toxin injections within the past 8 months for any indication and in any body part., Subject with predominant stress incontinence based on MESA incontinence score and/or voiding diary at screening., BMI = 35 kg/m2., If used should be on stable doses of diuretics for the past 3 months., Subjects who have any implanted electronic devices (a pacemaker, for example), permanent or transient, that cannot be removed prior to the treatment., Subjects who have received tibial or sacral nerve stimulation (SNS) anytime in the past or percutaneous tibial nerve (PTNS) in the last 3 months., Previous urinary incontinence surgery or prolapse surgery or de novo urinary incontinence post-surgery within the last 12 months., Any spinal surgery within the last 12 months., Allergy to Botulinum neurotoxin type A or any of the other ingredients and components of this device or the drug, Previous abdominoperineal resection of the rectum or previous radical hysterectomy., Diagnosis of interstitial cystitis or bladder pain syndrome as defined by either American Urological Association (AUA) or European Association of Urology (EAU) guidelines., History of evidence of anatomic pelvic, urological or urogenital abnormality according to investigator’s discretion., If used, subjects should be on stable dose of antimuscarinics and/or beta-3 adrenergic agonists for at least 3 months prior to enrolment and agree to remain on stable medication consumption until the 12-weeks follow-up visit., If used, subjects should be on a stable dose of tricyclic antidepressants, Selective Serotonin Reuptake Inhibitors (SSRI) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) for at least 3 months prior to enrolment and agree to remain on stable medication consumption until the 12 weeks follow-up visit., Subject with abnormal renal function defined by estimated glomerular filtration rate (eGFR) of 30 ml/min or less., History of pelvic radiotherapy or chemotherapy for pelvic malignancies., Diabetes with peripheral nerve neuropathy or severe uncontrolled diabetes (with HbA1C > 7.5%)., Uterine prolapse, cystocele, enterocele or rectocele past the hymen., Deemed unsuitable for enrollment by the investigator based on history or physical examination., Subject with OAB caused by neurological conditions (i.e., Myasthenia Gravis, ALS, Eaton-Lambert Syndrome, etc.), Any psychiatric or personality disorder at the discretion of the study physician., Any severe or uncontrolled systemic disease (e.g., cardiac, renal, pulmonary, hepatic, or gastrointestinal), malignant tumor, or medical history of HIV infection, or any findings from laboratory or physical examination performed at screening at the discretion of the investigator, Subject is breastfeeding., Drug or alcohol abuse, Any neurological disease or disorder including Alzheimer’s, Parkinson, MS, stroke (CVA), neuropathy or injury resulting in neuropathy., Subject currently under treatment with biofeedback, pelvic muscle rehabilitation, pelvic floor physical therapy. If willing to discontinue will be allowed to participate
研究者
相似试验
尚未招募
4 期
A prospective, multicenter, randomized, open study on the efficacy and safety of Yisaipu combined with traditional Chinese medicine for standard treatment and maintenance therapy in RA patients who failed traditional DMARDs treatmentRheumatoid arthritisITMCTR1900002628Guang'anmen Hospital, China Academy of Chinese Medical Sciences
招募中
3 期
A comparative clinical trial to test efficacy and safety of 2 brands of highly purified follicle-stimulating hormone in subjects undergoing IVFCTRI/2010/091/000852Bharat Serums and Vaccines Limited100
招募中
3 期
A comparative clinical trial to test efficacy and safety of 2 brands of highly purified human menopausal gonadotropins in subjects undergoing their first cycle of IVFCTRI/2009/091/000854Bharat Serums and Vaccines Limited100
进行中（未招募）
1 期
A study to compare the effects and safety of gadoquatrane with an already used available contrast agent for MRI tests in people with any known or suspected problems (except brain or spinal cord-related problems)Contrast enhancement in magnetic resonance imaging for assessment of non-central nervous system pathologyMedDRA version: 20.0Level: LLTClassification code: 10051174Term: Peripheral nerve disorder NOS Class: 10029205MedDRA version: 22.1Level: PTClassification code: 10078223Term: Magnetic resonance imaging Class: 100000004848MedDRA version: 22.1Level: LLTClassification code: 10029820Term: Nuclear magnetic resonance imaging gadolinium-enhanced Class: 10022891CTIS2022-501885-24-00Bayer AG664
进行中（未招募）
不适用
A prospective, randomized, open, multi-centre study to assess safety of PURETHAL Grasses given with a rush induction schedule to patients with allergic rhinoconjunctivitis. - PURETHAL Grasses Rush studyAllergic (IgE-mediated) rhinitis/rhinoconjunctivitis due to sensitization to grass pollenMedDRA version: 12.0Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisMedDRA version: 12.0Level: LLTClassification code 10001726Term: Allergic rhinitis due to pollenMedDRA version: 12.0Level: LLTClassification code 10053741Term: Allergenic desensitization procedureEUCTR2009-015012-18-DEHAL Allergy BV